These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 30249425)
1. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ Vaccine; 2018 Oct; 36(45):6810-6818. PubMed ID: 30249425 [TBL] [Abstract][Full Text] [Related]
2. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457 [TBL] [Abstract][Full Text] [Related]
3. Costs of herpes zoster complications in older adults: A cohort study of US claims database. Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248 [TBL] [Abstract][Full Text] [Related]
4. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565 [TBL] [Abstract][Full Text] [Related]
5. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285 [TBL] [Abstract][Full Text] [Related]
6. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014. Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Orrico-Sánchez A BMC Infect Dis; 2020 Nov; 20(1):905. PubMed ID: 33256624 [TBL] [Abstract][Full Text] [Related]
7. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871 [TBL] [Abstract][Full Text] [Related]
8. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601 [No Abstract] [Full Text] [Related]
9. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study. Mao J; McPheeters JT; Finelli L Medicine (Baltimore); 2017 Dec; 96(48):e8746. PubMed ID: 29310348 [TBL] [Abstract][Full Text] [Related]
10. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Insinga RP; Itzler RF; Pellissier JM Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857 [TBL] [Abstract][Full Text] [Related]
11. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817 [TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs associated with herpes zoster in the US. Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530 [TBL] [Abstract][Full Text] [Related]
13. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant. Mao J; McPheeters JT; Zhang D; Acosta CJ; Finelli L Curr Med Res Opin; 2018 Apr; 34(4):741-749. PubMed ID: 28945107 [TBL] [Abstract][Full Text] [Related]
14. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant. Palmer L; White RR; Johnson BH; Fowler R; Acosta CJ Transplantation; 2014 Jun; 97(11):1178-84. PubMed ID: 24892964 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
16. Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults. Karki S; Newall AT; MacIntyre CR; Heywood AE; McIntyre P; Banks E; Liu B PLoS One; 2016; 11(8):e0160446. PubMed ID: 27483007 [TBL] [Abstract][Full Text] [Related]
17. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost. Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238 [TBL] [Abstract][Full Text] [Related]
18. Incidence of herpes zoster and its complications in Germany, 2005-2009. Hillebrand K; Bricout H; Schulze-Rath R; Schink T; Garbe E J Infect; 2015 Feb; 70(2):178-86. PubMed ID: 25230396 [TBL] [Abstract][Full Text] [Related]
19. The temporal impact of aging on the burden of herpes zoster. Varghese L; Standaert B; Olivieri A; Curran D BMC Geriatr; 2017 Jan; 17(1):30. PubMed ID: 28114907 [TBL] [Abstract][Full Text] [Related]
20. Economic Burden of Herpes Zoster ("culebrilla") in Latin America. Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]